TCR2Therapeutics Inc. announced the appointment of Peter Olagunju as Chief Technical Officer where he will oversee process development, manufacturing, quality control and technical operations for the company’s TRuC-T cell programs and emerging pipeline. Mr. Olagunju brings to TCR2 over 20 years of experience in cell and gene therapy, clinical development, program management, manufacturing and technical operations. Prior to joining the Company, he was Senior Vice President of Technical Operations at FerGene Inc., where he led the technical operations function for the commercialization of a gene therapy for bladder cancer. Before that, Mr. Olagunju was Vice President of Global Patient Operations at bluebird bio Inc.